
Telix glioma PET agent moves toward FDA decision
The FDA assigned a September 11, 2026, PDUFA goal date for Pixclara, an investigational F-18 FET PET agent for glioma imaging.
Section
Every story we've published, newest first. 318 articles.

The FDA assigned a September 11, 2026, PDUFA goal date for Pixclara, an investigational F-18 FET PET agent for glioma imaging.

The 5-year contract covers cloud deployment of Visage 7 Viewer and Visage 7 Workflow across the University of Maryland Medical System.

The integration brings live intraoperative ultrasound images into the Stealth AXiS surgical navigation workflow for cranial procedures.

The approvals cover Hyperfine’s next-generation portable brain MRI system and the latest Optive AI software, with European and U.K. commercialization planned for early Q3 2026.

Steve MacMillan will step down after more than 12 years leading Hologic, as the company completes its acquisition by Blackstone and TPG.

Siemens Healthineers will radiolabel and distribute F-18 RAD101 doses in the U.S. to support Radiopharm’s planned Phase 3 registrational trial.

The Ashland, MO, facility will support commercial-scale production of Eye90 microspheres, a Y-90 radioembolization device in clinical development for liver cancer.

The $12.6M award advances AI4AD2, the second phase of a project using brain imaging, genomics, cognitive testing, and other data to study Alzheimer’s disease.

The national poll found that 42% of U.S. adults were open to AI use in their care, down from 52% in 2024.

SIIM and the Digital Pathology Association launched the SIIM-DPA Bridge Pass, giving members bundled access to SIIM26 in Pittsburgh and Pathology Visions 2026 in San Diego through a single payment.